Horizon Pharma PLC (NASDAQ:HZNP) – Stock analysts at Cantor Fitzgerald raised their FY2018 earnings estimates for shares of Horizon Pharma in a research note issued to investors on Sunday, according to Zacks Investment Research. Cantor Fitzgerald analyst L. Chen now expects that the biopharmaceutical company will earn $1.43 per share for the year, up from their prior forecast of $1.21. Cantor Fitzgerald currently has a “Buy” rating and a $17.00 target price on the stock.
Horizon Pharma (NASDAQ:HZNP) last announced its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.07. The business had revenue of $274.22 million during the quarter, compared to analysts’ expectations of $264.48 million. Horizon Pharma had a positive return on equity of 18.44% and a negative net margin of 38.87%. The business’s quarterly revenue was down 11.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.64 EPS.
Several other equities analysts have also recently issued reports on HZNP. UBS Group set a $20.00 price objective on Horizon Pharma and gave the company a “buy” rating in a research note on Thursday, November 30th. BidaskClub upgraded Horizon Pharma from a “hold” rating to a “buy” rating in a research note on Friday, December 22nd. ValuEngine cut Horizon Pharma from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Mizuho upgraded Horizon Pharma from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $12.00 to $18.00 in a research note on Friday, January 12th. Finally, Cowen restated a “buy” rating and set a $24.00 target price on shares of Horizon Pharma in a research note on Thursday, March 1st. One research analyst has rated the stock with a sell rating, three have given a hold rating and ten have issued a buy rating to the company’s stock. Horizon Pharma presently has a consensus rating of “Buy” and a consensus price target of $18.64.
Shares of Horizon Pharma (NASDAQ HZNP) traded up $0.06 on Wednesday, hitting $15.31. The stock had a trading volume of 1,450,000 shares, compared to its average volume of 1,910,000. The company has a quick ratio of 1.54, a current ratio of 1.63 and a debt-to-equity ratio of 1.91. The stock has a market cap of $2,500.00, a PE ratio of -5.14, a PEG ratio of 0.66 and a beta of 1.34. Horizon Pharma has a fifty-two week low of $9.45 and a fifty-two week high of $16.02.
A number of hedge funds have recently bought and sold shares of the stock. William Blair Investment Management LLC lifted its stake in Horizon Pharma by 12.2% during the fourth quarter. William Blair Investment Management LLC now owns 8,826,079 shares of the biopharmaceutical company’s stock worth $128,861,000 after purchasing an additional 958,414 shares during the last quarter. Sterling Capital Management LLC acquired a new position in Horizon Pharma during the fourth quarter worth approximately $1,340,000. Segall Bryant & Hamill LLC increased its position in Horizon Pharma by 12.6% during the fourth quarter. Segall Bryant & Hamill LLC now owns 725,002 shares of the biopharmaceutical company’s stock worth $10,585,000 after buying an additional 81,074 shares during the period. Redmile Group LLC acquired a new position in Horizon Pharma during the fourth quarter worth approximately $292,000. Finally, Cowen Inc. acquired a new position in Horizon Pharma during the fourth quarter worth approximately $781,000. Hedge funds and other institutional investors own 86.77% of the company’s stock.
About Horizon Pharma
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.